1. Multicentre retrospective analysis on pulmonary metastasectomy: an European perspective.
- Author
-
Prisciandaro, Elena, Bertolaccini, Luca, Fieuws, Steffen, Cara, Andrea, Spaggiari, Lorenzo, Huang, Lin, Petersen, René H, Ambrogi, Marcello C, Sicolo, Elisa, Barbarossa, Annalisa, Leyn, Paul De, Sporici, Diana, Balsamo, Ludovica, Donlagic, Abid, Gonzalez, Michel, Fuentes-Gago, Marta G, Forcada-Barreda, Clara, Congedo, Maria T, Margaritora, Stefano, and Belaroussi, Yaniss
- Subjects
METASTASECTOMY ,PNEUMONECTOMY ,VIDEO-assisted thoracic surgery ,LYMPHADENECTOMY ,RETROSPECTIVE studies ,LUNG surgery - Abstract
Open in new tab Download slide OBJECTIVES To assess the current practice of pulmonary metastasectomy at 15 European Centres. Short- and long-term outcomes were analysed. METHODS Retrospective analysis on patients ≥18 years who underwent curative-intent pulmonary metastasectomy (January 2010 to December 2018). Data were collected on a purpose-built database (REDCap). Exclusion criteria were: previous lung/extrapulmonary metastasectomy, pneumonectomy, non-curative intent and evidence of extrapulmonary recurrence at the time of lung surgery. RESULTS A total of 1647 patients [mean age 59.5 (standard deviation; SD = 13.1) years; 56.8% males] were included. The most common primary tumour was colorectal adenocarcinoma. The mean disease-free interval was 3.4 (SD = 3.9) years. Relevant comorbidities were observed in 53.8% patients, with a higher prevalence of metabolic disorders (32.3%). Video-assisted thoracic surgery was the chosen approach in 54.9% cases. Wedge resections were the most common operation (67.1%). Lymph node dissection was carried out in 41.4% cases. The median number of resected lesions was 1 (interquartile range 25–75% = 1–2), ranging from 1 to 57. The mean size of the metastases was 18.2 (SD = 14.1) mm, with a mean negative resection margin of 8.9 (SD = 9.4) mm. A R0 resection of all lung metastases was achieved in 95.7% cases. Thirty-day postoperative morbidity was 14.5%, with the most frequent complication being respiratory failure (5.6%). Thirty-day mortality was 0.4%. Five-year overall survival and recurrence-free survival were 62.0% and 29.6%, respectively. CONCLUSIONS Pulmonary metastasectomy is a low-risk procedure that provides satisfactory oncological outcomes and patient survival. Further research should aim at clarifying the many controversial aspects of its daily clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF